Early responses to adenoviral-mediated transfer of the aquaporin-1 cDNA for radiation-induced salivary hypofunction

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 47, 2012, Pages 19403-19407

  Baum, Bruce J ^a   Alevizos, Ilias ^a   Zheng, Changyu ^a   Cotrim, Ana P ^a   Liu, Shuying ^a   McCullagh, Linda ^a   Goldsmith, Corinne M ^a   Burbelo, Peter D ^a   Citrin, Deborah E ^b   Mitchell, James B ^b   Nottingham, Liesl K ^c   Rudy, Susan F ^c   Van Waes, Carter ^c   Whatley, Millie A ^d   Brahim, Jaime S ^d   Chiorini, John A ^a   Danielides, Stamatina ^a   Turner, R James ^a   Patronas, Nicholas J ^e   Chen, Clara C ^d   Nikolov, Nikolay P ^a   Illei, Gabor G ^a   more..

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

Author keywords

Dry mouth; Gene therapy; Radiation damage; Salivary glands; Water channel

Indexed keywords

ADENOVIRUS VECTOR; AQUAPORIN 1; COMPLEMENTARY DNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL CHEMISTRY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOLOGY; HUMAN; MALE; PAROTID GLAND CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION INDUCED SALIVARY HYPOFUNCTION; RADIATION INJURY; SALIVATION; SALIVATION DISORDER; TREATMENT RESPONSE; VISUAL ANALOG SCALE; XEROSTOMIA;

ADENOVIRIDAE; AGED; AQUAPORIN 1; CITRATES; DNA, COMPLEMENTARY; GALLIUM; GENETIC THERAPY; HUMANS; MALE; MIDDLE AGED; RADIATION INJURIES; SALIVARY GLAND DISEASES;

EID: 84869786890     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1210662109     Document Type: Article

References (29)

1. Jemal A, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225-249.
2. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5):1341-1346.
3. Jensen SB, et al.; Salivary Gland Hypofunction/Xerostomia Section; Oral Care Study Group; Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: Management strategies and economic impact. Support Care Cancer 18(8):1061-1079.
4. Vissink A, et al. (2010) Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: Successes and barriers. Int J Radiat Oncol Biol Phys 78(4):983-991.
5. Amerongen AV, Veerman EC (2002) Saliva - The defender of the oral cavity. Oral Dis 8(1):12-22.
6. Jensen SB, et al.; Salivary Gland Hypofunction/Xerostomia Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: Prevalence, severity and impact on quality of life. Support Care Cancer 18(8):1039-1060.
7. Baum BJ (1993) Principles of saliva secretion. Ann N Y Acad Sci 694:17-23.
8. Baum BJ, et al. (2010) Development of a gene transfer-based treatment for radiation-induced salivary hypofunction. Oral Oncol 46(1):4-8.
9. Delporte C, et al. (1997) Increased fluid secretion after adenoviral-mediated transfer of the aquaporin-1 cDNA to irradiated rat salivary glands. Proc Natl Acad Sci USA 94(7):3268-3273.
10. Shan Z, et al. (2005) Increased fluid secretion after adenoviral-mediated transfer of the human aquaporin-1 cDNA to irradiated miniature pig parotid glands. Mol Ther 11(3):444-451.
11. Zheng C, et al. (2006) Toxicity and biodistribution of a first-generation recombinant adenoviral vector, encoding aquaporin-1, after retroductal delivery to a single rat submandibular gland. Hum Gene Ther 17(11):1122-1133.
12. Zheng C, et al. (2010) Transient detection of E1-containing adenovirus in saliva after the delivery of a first-generation adenoviral vector to human parotid gland. J Gene Med 12(1):3-10.
13. Crystal RG, et al. (2002) Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum Gene Ther 13(1):65-100.
14. Harvey BG, et al. (2002) Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 13(1):15-63.
15. Gao R, et al. (2011) AAV2-mediated transfer of the human aquaporin-1 cDNA restores fluid secretion from irradiated miniature pig parotid glands. Gene Ther 18(1):38-42.
16. Campochiaro PA, et al. (2006) Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: Results of a phase I clinical trial. Hum Gene Ther 17(2):167-176.
17. Harvey BG, et al. (1999) Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest 104(9):1245-1255.
18. Mäkinen K, et al. (2002) Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: A randomized, placebo- controlled, double-blinded phase II study. Mol Ther 6(1):127-133.
19. Rosengart TK, et al. (1999) Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100(5):468-474.
20. Kagami H, O'Connell BC, Baum BJ (1996) Evidence for the systemic delivery of a transgene product from salivary glands. Hum Gene Ther 7(17):2177-2184.
21. Li J, et al. (2004) Developing a convenient large animal model for gene transfer to salivary glands in vivo. J Gene Med 6(1):55-63.
22. Voutetakis A, et al. (2008) Sorting of transgenic secretory proteins in rhesus macaque parotid glands after adenovirus-mediated gene transfer. Hum Gene Ther 19(12):1401-1405.
23. Wang S, et al. (2000) Adenoviral-mediated gene transfer to mouse salivary glands. J Dent Res 79(2):701-708.
24. Wold WSM, Horwitz MS (2007) Adenoviruses. Fields' Virology, 5th ed. Eds Fields BN, Knipe DM, Howley PM, (Lippincott Williams & Wilkins, Philadelphia PA).
25. Bellon G, et al. (1997) Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: A phase I clinical trial. Hum Gene Ther 8(1):15-25.
26. Matyas L, et al. (2005) Arteriogenic gene therapy in patients with unreconstructable critical limb ischemia: A randomized, placebo-controlled clinical trial of adenovirus 5- delivered fibroblast growth factor-4. Hum Gene Ther 16(10):1202-1211.
27. Zuckerman JB, et al. (1999) A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther 10(18):2973-2985.
28. Harvey BG, et al. (1999) Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol 73(8):6729-6742.
29. Samuni Y, Baum BJ (2011) Gene delivery in salivary glands: From the bench to the clinic. Biochim Biophys Acta 1812(11):1515-1521.